Bumetanide inhibited NKCC1-mediated chloride influx in a HEK293 reporter assay at 100 μM. In a separate HEK293 assay, 10 μM bumetanide also inhibited NKCC2-mediated chloride influx. These experiments support activity at both cotransporters; their treatment concentrations are not interchangeable IC50 values. [1,2]
Bumetanide occupies the extracellular NKCC1 ion pathway
Biochemical assay · Purified full-length human phospho-activated NKCC1, produced in HEK293T/17 SF cells co-expressing WNK1(1–483, S378D), Mo25 and SPAK. [1]
The bumetanide co-structure places the compound in the extracellular vestibule of an outward-open NKCC1. Its carboxyl group coordinates a co-occluded K+ ion. This is structural evidence for occlusion of the transport pathway, not a binding-affinity measurement.
Literature-Reported Treatment Conditions
- Treatment concentration
- 100 μM during membrane preparation and protein purification
- Exposure duration
- Maintained through purification
- Method
- Single-particle cryo-EM of the purified bumetanide/NKCC1 complex
- Reported limits
- No dissociation constant measured by this structural experiment; no supplier lot specified.
Methods and source locations
Compound reported in the paper: Bumetanide; Compound label in the paper: bumetanide
Compound-level evidence for bumetanide; no Adooq lot or formulation validation.
Results: Overall architecture; Two modes of NKCC1 antagonism; Fig. EV2A,B; Fig. EV3B; Methods: expression/purification and EM reconstruction
Position of bound bumetanide and K+ in the NKCC1 ion pathway: Single-particle cryo-EM; interpretation of ligand and ion densities. — Fig. EV2A,B; Fig. EV3B; Results: Two modes of NKCC1 antagonism
Inhibition of NKCC1-mediated chloride influx in HEK293 cells
Cell-based study · HEK293T/17 SF stable cells expressing human Twin-Strep-NKCC1 and membrane-targeted Cl−-sensitive mbYFPQS. [1]
Externally applied bumetanide inhibited the NKCC1-associated fluorescence response to chloride addition. Reporter-only cells were included as a negative control. The concentration-response experiment used four biological repeats with mean ± SD; no exact IC50 is extracted from the plotted curve.
Literature-Reported Treatment Conditions
- Treatment concentration
- 100 μM for inhibitor validation; a concentration-response series is also shown
- Exposure duration
- Activation-buffer incubation 2–3 h; transport rates derived from the initial 20 s after assay-buffer exchange
- Method
- Extracellular addition in activation and assay buffers; mbYFPQS fluorescence assay
- Reported limits
- Vehicle for bumetanide is not specified in the read assay methods. Individual dose-series exposure timing is not separately described.
Methods and source locations
Compound reported in the paper: Bumetanide; Compound label in the paper: bumetanide
Compound-level evidence for bumetanide; no Adooq lot or formulation validation.
Fig. EV1A–D; Methods: Cl− influx assay in HEK293 cells; reagents table
NKCC1-mediated chloride transport: mbYFPQS fluorescence; slopes over the first 20 s after chloride addition; reporter-only negative control. — Fig. EV1A,B; Methods: Cl− influx assay
Bumetanide also inhibits NKCC2-mediated chloride influx
Cell-based study · HEK293 cells transfected with NKCC2 and mbYFPQS, with mock-transfected cells for background subtraction. [2]
Bumetanide at 10 μM inhibited NKCC2-mediated chloride influx relative to DMSO control. ARN23746 was tested in parallel and did not significantly inhibit NKCC2 under these conditions. The bumetanide result limits an NKCC1-selective interpretation.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 μM
- Exposure duration
- 30 min pretreatment; 20 s baseline followed by 60 s recording after NaCl addition
- Method
- Cl−-sensitive mbYFPQS assay; final 74 mM NaCl; endpoint uses the final 10 s of normalized fluorescence
- Vehicle
- 0.1% DMSO control
- Reported limits
- Bumetanide lot and a separate in-vitro supplier are not specified in the read methods.
Methods and source locations
Compound reported in the paper: Bumetanide; Compound label in the paper: Bume
Evidence concerns the named parent compound in the stated assay; no supplier equivalence or Adooq lot validation.
Fig. 2B; Results: Design and Synthesis of NKCC1 Novel Inhibitors; Methods: HEK Cell Culture and Transfection; Cl− Influx Assay
NKCC2-associated fluorescence decrease after chloride addition: Mock-subtracted mbYFPQS response, normalized to DMSO; Kruskal–Wallis test with Dunn’s post hoc test. — Fig. 2B and caption; corresponding Results paragraph; Cl− influx Methods